Switch theme
Sign up to access all valuation multiples
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
2002
1.5K+
LTM Revenue $301M
LTM EBITDA $48.5M
$396M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Takara Bio has a last 12-month revenue of $301M and a last 12-month EBITDA of $48.5M.
In the most recent fiscal year, Takara Bio achieved revenue of $289M and an EBITDA of $52.5M.
Takara Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Takara Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $519M | $289M | XXX | XXX | XXX |
| Gross Profit | $327M | $298M | XXX | XXX | XXX |
| Gross Margin | 63% | 103% | XXX | XXX | XXX |
| EBITDA | $173M | $52.5M | XXX | XXX | XXX |
| EBITDA Margin | 33% | 18% | XXX | XXX | XXX |
| Net Profit | $132M | $106M | XXX | XXX | XXX |
| Net Margin | 25% | 37% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Takara Bio's stock price is JPY 781 (or $5).
Takara Bio has current market cap of JPY 94.0B (or $625M), and EV of JPY 59.6B (or $396M).
See Takara Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $396M | $625M | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Takara Bio has market cap of $625M and EV of $396M.
Takara Bio's trades at 1.3x LTM EV/Revenue multiple, and 8.2x LTM EBITDA.
Analysts estimate Takara Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Takara Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $396M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | XXX | XXX |
| P/E | 69.5x | XXX | XXX | XXX |
| P/E/Growth | 1.6x | XXX | XXX | XXX |
| EV/FCF | -21.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTakara Bio's NTM/LTM revenue growth is 4%
Takara Bio's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Takara Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Takara Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Takara Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -44% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -70% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 21% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 55% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Corbion | XXX | XXX | XXX | XXX | XXX | XXX |
| Gujarat State Fertilizers & Chemicals | XXX | XXX | XXX | XXX | XXX | XXX |
| Industries Qatar | XXX | XXX | XXX | XXX | XXX | XXX |
| K+S | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Takara Bio acquired XXX companies to date.
Last acquisition by Takara Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Takara Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Takara Bio founded? | Takara Bio was founded in 2002. |
| Where is Takara Bio headquartered? | Takara Bio is headquartered in Japan. |
| How many employees does Takara Bio have? | As of today, Takara Bio has 1.5K+ employees. |
| Who is the CEO of Takara Bio? | Takara Bio's CEO is Mr. Koichi Nakao. |
| Is Takara Bio publicy listed? | Yes, Takara Bio is a public company listed on TKS. |
| What is the stock symbol of Takara Bio? | Takara Bio trades under 4974 ticker. |
| When did Takara Bio go public? | Takara Bio went public in 2004. |
| Who are competitors of Takara Bio? | Similar companies to Takara Bio include e.g. Fertiglobe, Corbion, Gujarat State Fertilizers & Chemicals, Industries Qatar. |
| What is the current market cap of Takara Bio? | Takara Bio's current market cap is $625M |
| What is the current revenue of Takara Bio? | Takara Bio's last 12-month revenue is $301M. |
| What is the current EBITDA of Takara Bio? | Takara Bio's last 12-month EBITDA is $48.5M. |
| What is the current EV/Revenue multiple of Takara Bio? | Current revenue multiple of Takara Bio is 1.3x. |
| What is the current EV/EBITDA multiple of Takara Bio? | Current EBITDA multiple of Takara Bio is 8.2x. |
| What is the current revenue growth of Takara Bio? | Takara Bio revenue growth between 2023 and 2024 was -44%. |
| Is Takara Bio profitable? | Yes, Takara Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
